Zenith Capital (Zenith Capital) Days Payable : 0.00 (As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Days Payable?

Zenith Capital's average Accounts Payable for the three months ended in . 20 was $0.00 Mil. Zenith Capital's Cost of Goods Sold for the three months ended in . 20 was $0.00 Mil.

The historical rank and industry rank for Zenith Capital's Days Payable or its related term are showing as below:

ZHCLF's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.145
* Ranked among companies with meaningful Days Payable only.

Zenith Capital's Days Payable stayed the same from . 20 (0.00) to . 20 (0.00). stayed the same

Zenith Capital Days Payable Historical Data

The historical data trend for Zenith Capital's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Days Payable Chart

Zenith Capital Annual Data

Trend

Days Payable

Zenith Capital Quarterly Data

Days Payable

Competitive Comparison of Zenith Capital's Days Payable

For the Biotechnology subindustry, Zenith Capital's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenith Capital's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's Days Payable distribution charts can be found below:

* The bar in red indicates where Zenith Capital's Days Payable falls into.

Zenith Capital Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Zenith Capital's Days Payable for the fiscal year that ended in . 20 is calculated as

	Days Payable (A: . 20 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: . 20 )	+	Accounts Payable (A: . 20 ))	/	count )	/	Cost of Goods Sold (A: . 20 )	*	Days in Period
=	( (	+	)	/	1 )	/		*	365
=	0					/		*	365
=	N/A

Zenith Capital's Days Payable for the quarter that ended in . 20 is calculated as:

	Days Payable (Q: . 20 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: . 20 )	+	Accounts Payable (Q: . 20 ))	/	count )	/	Cost of Goods Sold (Q: . 20 )	*	Days in Period
=	( (	+	)	/	1 )	/		*	365 / 4
=	0					/		*	365 / 4
=	N/A

Zenith Capital Days Payable Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines